{"nctId":"NCT05028634","briefTitle":"Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy","startDateStruct":{"date":"2021-11-11","type":"ACTUAL"},"conditions":["Multiple Sclerosis","Multiple Sclerosis, Relapsing-Remitting"],"count":63,"armGroups":[{"label":"Cohort 1 - Ozanimod","type":"EXPERIMENTAL","interventionNames":["Biological: Tetanus, diphtheria, and acellular pertussis vaccine","Biological: Pneumococcal polysaccharide vaccine","Biological: Seasonal influenza vaccine"]},{"label":"Cohort 1 - non-pegylated interferon-β or no disease modifying therapy","type":"EXPERIMENTAL","interventionNames":["Biological: Tetanus, diphtheria, and acellular pertussis vaccine","Biological: Pneumococcal polysaccharide vaccine","Biological: Seasonal influenza vaccine"]},{"label":"Cohort 2 - Ozanimod","type":"EXPERIMENTAL","interventionNames":["Biological: Tetanus, diphtheria, and acellular pertussis vaccine","Biological: Pneumococcal polysaccharide vaccine"]},{"label":"Cohort 2 - non-pegylated interferon-β or no disease modifying therapy","type":"EXPERIMENTAL","interventionNames":["Biological: Tetanus, diphtheria, and acellular pertussis vaccine","Biological: Pneumococcal polysaccharide vaccine"]}],"interventions":[{"name":"Tetanus, diphtheria, and acellular pertussis vaccine","otherNames":["Tdap"]},{"name":"Pneumococcal polysaccharide vaccine","otherNames":["PPSV23"]},{"name":"Seasonal influenza vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant has a diagnosis of multiple sclerosis (MS) according to the 2017 revision of the McDonald diagnostic criteria and has relapsing forms of multiple sclerosis (RMS): relapsing-remitting MS (RRMS) or secondary progressive MS with active disease based on recent clinical relapse or MRI lesion activity.\n\nExclusion Criteria:\n\n* Participant has history of cancer, including solid tumors and hematological except for basal cell cancer of the skin and carcinoma in situ of the cervix, which are exclusionary if they have not been excised and resolved.\n* Participant has a history of or currently active primary or secondary immunodeficiency.\n* Participant has severely compromised cardiac or pulmonary function for which a systemic hypersensitivity reaction to any of the vaccines would pose a significant risk.\n* Participant has received the seasonal influenza vaccine for the 2021/2022 influenza season prior to Day 1, or history of influenza vaccine for the 2020/2021 influenza season within 6 months prior to Day 1.\n* Participant has previous treatment with one of the following medications or interventions within the corresponding timeframe described as follows:\n\n  * Any systemic immunosuppressive treatments with potential overlapping effects with the baseline of this study. Corticosteroids that are by non-systemic routes (e.g., topical, inhaled, intra-articular) are allowed.\n* History of treatment with IV immunoglobulin (IVIg) or plasmapheresis within 4 weeks prior to Day 1.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Meeting Immune Serological Response Criteria to Tetanus Toxoid Antigen","description":"Serologic response to tetanus toxoid criteria are as follows - if pre vaccination antibody titer is ≤0.10 IU/mL, post-vaccination level ≥0.40 IU/mL; if pre-vaccination antibody titer is \\>0.10 IU/mL and ≤2.7 IU/mL, at least a 4-fold increase in titer; if pre-vaccination antibody titer is\\>2.7 IU/mL, at least a 2-fold increase in titer.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"53.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Meeting Immune Serological Protection Criteria to Tetanus Toxoid Antigen","description":"Participants with Serological protection to tetanus toxoid have anti-tetanus toxoid IgG concentration \\>= 0.1 International Units per milliliter (IU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serologic Response to Pneumococcal Polysaccharide Vaccine (PPSV23)","description":"Serological response to PPSV23 was defined as the percentage of participants with a ≥2-fold increase in anti-pneumococcal polysaccharide vaccine titer in \\>5 of the indicated serotypes - 3, 6B, 9N, 11A, 14, 19A, 19F, 22F and 23F","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serologic Protection Against Pneumococcal Polysaccharide Vaccine (PPSV23)","description":"Serological protection against PPSV23 was defined as the percentage of participants with Anti-pneumococcal polysaccharide IgG concentration \\>= 1.3 μg/mL in the indicated serotypes - 3, 6B, 9N, 11A, 14, 19A, 19F, 22F and 23F associated with increased risk of invasive and/or severe disease, including death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"71.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"Adverse events include events with onset date on or after the study medication first dose date until end of study visit after the vaccine administration. Serious AEs was defined as is any AE occurring at any dose of vaccination from Day 1 to the end of the study that results in death, Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate risk of death from the AE), Requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or constitutes an important medical event.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormalities in Blood Chemistry Parameters","description":"Blood samples were collected to assess laboratory parameters","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormalities in Blood Hematology Parameters","description":"Blood samples were collected to assess laboratory parameters","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Chemistry Parameters - Sodium; Potassium; Chloride; Calcium; Magnesium; Phosphate; Blood Urea Nitrogen; Glucose","description":"Blood samples were collected to assess laboratory parameters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.90"},{"groupId":"OG001","value":"-0.3","spread":"2.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.637"},{"groupId":"OG001","value":"-0.08","spread":"0.315"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"5.19"},{"groupId":"OG001","value":"0.2","spread":"2.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.044","spread":"0.0881"},{"groupId":"OG001","value":"-0.015","spread":"0.0888"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.003","spread":"0.0572"},{"groupId":"OG001","value":"-0.001","spread":"0.0549"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.011","spread":"0.2197"},{"groupId":"OG001","value":"-0.041","spread":"0.1640"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.044","spread":"1.1424"},{"groupId":"OG001","value":"0.165","spread":"1.1542"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"0.845"},{"groupId":"OG001","value":"0.08","spread":"0.946"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Chemistry Parameters - Creatinine; Bilirubin; Direct Bilirubin","description":"Blood samples were collected to assess laboratory parameters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"9.64"},{"groupId":"OG001","value":"-0.6","spread":"9.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.81"},{"groupId":"OG001","value":"0.1","spread":"3.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.20"},{"groupId":"OG001","value":"0.0","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Chemistry Parameters - Albumin","description":"Blood samples were collected to assess laboratory parameters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.67"},{"groupId":"OG001","value":"-0.8","spread":"2.91"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Chemistry Parameters - Alkaline Phosphatase","description":"Blood samples were collected to assess laboratory parameters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"14.48"},{"groupId":"OG001","value":"-1.1","spread":"8.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Chemistry Parameters - Alanine Aminotransferase; Aspartate Aminotransferase; Gamma Glutamyl Transferase","description":"Blood samples were collected to assess laboratory parameters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"8.88"},{"groupId":"OG001","value":"1.4","spread":"5.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"3.77"},{"groupId":"OG001","value":"0.9","spread":"5.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"23.09"},{"groupId":"OG001","value":"0.6","spread":"8.39"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Hematology Parameters - Erythrocytes","description":"Blood samples were collected to assess laboratory parameters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.191"},{"groupId":"OG001","value":"-0.07","spread":"0.265"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Hematology Parameters - Leukocytes; Basophils; Eosinophils; Lymphocytes; Monocytes; Neutrophils; Platelets","description":"Blood samples were collected to assess laboratory parameters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"1.271"},{"groupId":"OG001","value":"0.33","spread":"1.298"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.013","spread":"0.0320"},{"groupId":"OG001","value":"-0.007","spread":"0.0253"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.038","spread":"0.2872"},{"groupId":"OG001","value":"0.013","spread":"0.1531"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.046","spread":"0.1806"},{"groupId":"OG001","value":"0.021","spread":"0.3580"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.021","spread":"0.1734"},{"groupId":"OG001","value":"0.025","spread":"0.1506"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.480","spread":"1.1208"},{"groupId":"OG001","value":"0.218","spread":"1.2622"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"37.08"},{"groupId":"OG001","value":"1.4","spread":"36.33"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Hematology Parameters - Basophils/Leukocytes; Eosinophils/Leukocytes; Lymphocytes/Leukocytes; Monocytes/Leukocytes; Neutrophils/Leukocytes","description":"Blood samples were collected to assess laboratory parameters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"0.528"},{"groupId":"OG001","value":"-0.14","spread":"0.442"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"3.919"},{"groupId":"OG001","value":"0.05","spread":"1.950"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"3.675"},{"groupId":"OG001","value":"-1.35","spread":"6.883"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"3.135"},{"groupId":"OG001","value":"0.03","spread":"2.192"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"6.750"},{"groupId":"OG001","value":"1.40","spread":"7.177"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Hematology Parameters - Hemoglobin; Erythrocytes Mean Corpuscular HGB Concentration","description":"Blood samples were collected to assess laboratory parameters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"5.67"},{"groupId":"OG001","value":"-2.9","spread":"7.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"9.81"},{"groupId":"OG001","value":"0.2","spread":"9.16"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Hematology Parameters - Erythrocytes Mean Corpuscular Volume","description":"Blood samples were collected to assess laboratory parameters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.25"},{"groupId":"OG001","value":"-0.5","spread":"1.95"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Hematology Parameters - Erythrocytes Mean Corpuscular Hemoglobin","description":"Blood samples were collected to assess laboratory parameters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.65"},{"groupId":"OG001","value":"-0.1","spread":"0.72"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Hematology Parameters - Hematocrit","description":"Blood samples were collected to assess laboratory parameters. Participants with baseline and post-baseline data available at the specified timepoint are included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.007","spread":"0.0226"},{"groupId":"OG001","value":"-0.010","spread":"0.0270"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Injection site pain","Fatigue","COVID-19","Urinary tract infection"]}}}